<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535974</url>
  </required_header>
  <id_info>
    <org_study_id>TiroNod</org_study_id>
    <nct_id>NCT03535974</nct_id>
  </id_info>
  <brief_title>Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules</brief_title>
  <acronym>ESSAY</acronym>
  <official_title>Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundatia Bio-Forum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundatia Bio-Forum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial with a double-blind, placebo-controlled, crossover design; enrolls
      approximately 30 euthyroid patients with benign thyroid nodules, who will receive for 6 weeks
      a spirulina-based supplement, and for another 6 weeks placebo. Thyroid ecography will be
      performed three times for each patient, and blood tests including TSH, free T4, free T3 and
      ceruloplasmin/Copper will also be performed 3 times for each patient. It is expected that a
      decrease in the thyroid nodules occurs with the supplement administration. Compared with
      placebo there will be a decrease of at least 20% in the volume or the largest diameter of the
      nodules during the 6-week administration of the supplement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trial with double-blind, placebo-controlled, crossover design; enrolls approximately
      30 euthyroid patients with benign thyroid nodules, who will receive for 6 weeks a
      spirulina-based supplement, and for another 6 weeks placebo.

        -  The sequence of administration supplement - placebo is unknown to the doctor or the
           patients

        -  The supplement and placebo are placed in identical capsules and vials by DVR Pharm

        -  The respective capsules are administered twice a day Thyroid ecography will be performed
           three times for each patient, and blood tests including TSH, free T4, free T3 and
           ceruloplasmin/Copper will also be performed 3 times for each patient.

        -  Echography and blood tests will be performed for each patient initially, after 6 weeks,
           and after 12 weeks It is expected that a decrease in the thyroid nodules occurs with the
           supplement administration.

        -  there will be a direct comparison of the nodules dimensions on the ecographic
           examinations, in millimeters, and of the blood levels of the molecules which reflect
           thyroid function
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2018</start_date>
  <completion_date type="Anticipated">December 21, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in size of thyroid nodules</measure>
    <time_frame>after 6 weeks of administration of the supplement and placebo</time_frame>
    <description>Largest diameter of the thyroid nodules measured by ecograph in millimeters, same incidence and operator</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Benign Thyroid Nodule</condition>
  <arm_group>
    <arm_group_label>Preparation with Spirulina</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 weeks bid Preparation with Spirulina</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 weeks bid Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Preparation with Spirulina</intervention_name>
    <description>Preparation with Spirulina to ameliorate the size of benign thyroid nodules</description>
    <arm_group_label>Preparation with Spirulina</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administration for 6 weeks bid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  euthyroid adults (normal TSH)

          -  no criteria for malignancy is present (size, fine needle aspiration, lymph nodules)

          -  no other medication/supplement administered for thyroid, no steroids, beta-blocker

        Exclusion Criteria:

          -  suspicion of malignancy / shown

          -  autoimmune disease

          -  abnormal thyroid function

          -  Wilson disease

          -  contraception with intrauterine device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corin Badiu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institutul Parhon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felician Stancioiu, M.D.</last_name>
    <phone>+40727500402</phone>
    <email>felicians11@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundatia Bio-Forum</name>
      <address>
        <city>Bucharest</city>
        <state>Bucuresti</state>
        <zip>040245</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felician Stancioiu, MD</last_name>
      <phone>0727500402</phone>
      <email>felicians11@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Felician Stancioiu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Nodule</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

